- Home
- BG vs EXEL Comparison
BG vs EXEL Comparison
Compare BG & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BG
- EXEL
- Stock Information
- Founded
- BG 1818
- EXEL 1994
- Country
- BG United States
- EXEL United States
- Employees
- BG N/A
- EXEL N/A
- Industry
- BG Packaged Foods
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BG Consumer Staples
- EXEL Health Care
- Exchange
- BG Nasdaq
- EXEL Nasdaq
- Market Cap
- BG 10.1B
- EXEL 9.4B
- IPO Year
- BG N/A
- EXEL 2000
- Fundamental
- Price
- BG $77.86
- EXEL $36.39
- Analyst Decision
- BG Buy
- EXEL Buy
- Analyst Count
- BG 4
- EXEL 18
- Target Price
- BG $90.00
- EXEL $37.59
- AVG Volume (30 Days)
- BG 1.9M
- EXEL 2.7M
- Earning Date
- BG 04-23-2025
- EXEL 04-29-2025
- Dividend Yield
- BG 3.52%
- EXEL N/A
- EPS Growth
- BG N/A
- EXEL 170.77
- EPS
- BG 7.99
- EXEL 1.76
- Revenue
- BG $53,108,000,000.00
- EXEL $2,168,701,000.00
- Revenue This Year
- BG $7.65
- EXEL $5.45
- Revenue Next Year
- BG $1.82
- EXEL $10.32
- P/E Ratio
- BG $9.66
- EXEL $20.68
- Revenue Growth
- BG N/A
- EXEL 18.50
- 52 Week Low
- BG $67.40
- EXEL $20.14
- 52 Week High
- BG $114.92
- EXEL $40.02
- Technical
- Relative Strength Index (RSI)
- BG 64.42
- EXEL 46.43
- Support Level
- BG $74.90
- EXEL $35.57
- Resistance Level
- BG $75.50
- EXEL $38.41
- Average True Range (ATR)
- BG 1.79
- EXEL 1.10
- MACD
- BG 0.42
- EXEL -0.19
- Stochastic Oscillator
- BG 99.48
- EXEL 28.87
About BG Bunge Limited
Bunge Global SA formerly Bunge Ltd is an agribusiness and food company with operations along the farm-to-consumer food chain. The company segments include Agribusiness; Refined and Specialty Oils; Milling; Sugar and Bioenergy and Corporate and Other. It generates maximum revenue from the Agribusiness segment. The company is an oilseed processor and producer of vegetable oils and protein meals, based on processing capacity, a grain processor, the seller of packaged plant-based oils, producer and seller of wheat flour, bakery mixes and corn-based products in North and South America.
About EXEL Exelixis Inc.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.